Other equities research analysts have also recently issued reports about the company. Shore Capital reiterated a buy rating on shares of Shire in a research note on Thursday, October 26th. Berenberg Bank cut their price objective on Shire from GBX 6,000 ($80.75) to GBX 5,900 ($79.41) and set a buy rating on the stock in a report on Tuesday, October 24th. Jefferies Group reissued a buy rating on shares of Shire in a report on Tuesday, August 22nd. Citigroup reissued a buy rating and issued a GBX 6,300 ($84.79) price objective on shares of Shire in a report on Tuesday, August 22nd. Finally, Kepler Capital Markets reissued a buy rating and issued a GBX 4,600 ($61.91) price objective on shares of Shire in a report on Wednesday, November 1st. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. Shire presently has an average rating of Buy and a consensus price target of GBX 5,277.78 ($71.03).
Shares of Shire (SHP) opened at GBX 3,754.50 ($50.53) on Monday. Shire has a 12 month low of GBX 3,435.50 ($46.24) and a 12 month high of GBX 5,067 ($68.20).
In related news, insider Anne Minto bought 190 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The shares were purchased at an average cost of GBX 3,785 ($50.94) per share, with a total value of £7,191.50 ($9,679.00).
ILLEGAL ACTIVITY NOTICE: This article was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://ledgergazette.com/2017/12/12/shire-shp-receives-buy-rating-from-deutsche-bank.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.